Solid Biosciences (NASDAQ:SLDB - Get Free Report) is expected to be issuing its Q4 2024 quarterly earnings data before the market opens on Thursday, March 6th. Analysts expect the company to announce earnings of ($0.79) per share for the quarter.
Solid Biosciences Stock Down 1.5 %
Shares of NASDAQ SLDB traded down $0.08 during midday trading on Friday, reaching $5.42. 1,674,204 shares of the company were exchanged, compared to its average volume of 2,931,747. The stock's 50-day moving average price is $4.07 and its 200-day moving average price is $5.58. The stock has a market cap of $413.65 million, a P/E ratio of -1.78 and a beta of 2.01. Solid Biosciences has a one year low of $2.88 and a one year high of $15.05.
Analysts Set New Price Targets
SLDB has been the topic of a number of research reports. Chardan Capital restated a "buy" rating and set a $16.00 price objective on shares of Solid Biosciences in a research report on Friday. Citizens Jmp upgraded Solid Biosciences to a "strong-buy" rating in a report on Tuesday, December 10th. Truist Financial started coverage on shares of Solid Biosciences in a report on Wednesday, January 8th. They issued a "buy" rating and a $16.00 price objective for the company. HC Wainwright reissued a "buy" rating and set a $16.00 target price on shares of Solid Biosciences in a report on Friday, January 10th. Finally, Wedbush started coverage on shares of Solid Biosciences in a research report on Friday, December 13th. They issued an "outperform" rating and a $16.00 price target for the company. Nine research analysts have rated the stock with a buy rating and four have given a strong buy rating to the company's stock. According to data from MarketBeat, Solid Biosciences presently has an average rating of "Buy" and an average price target of $15.40.
View Our Latest Analysis on SLDB
About Solid Biosciences
(
Get Free Report)
Solid Biosciences Inc, a life science company, develops therapies for neuromuscular and cardiac diseases in the United States. The company's lead product candidate is SGT-003, a gene transfer candidate for the treatment of Duchenne muscular dystrophy; and SGT-501 to treat Catecholaminergic polymorphic ventricular tachycardia.
Featured Stories
Before you consider Solid Biosciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Solid Biosciences wasn't on the list.
While Solid Biosciences currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
